H. Lundbeck (LUN) CMD 2024 summary

Strategic direction and innovation

• Focused Innovator strategy drives sustainable growth through targeted innovation, capital reallocation, and a patient-centric neuroscience approach, with commercial model optimization and specialty market focus.

• Strategic brands Rexulti, Vyepti, and Brintellix/Trintellix are prioritized, accounting for about 70% of strategic brand sales and nearly 60% of total revenue in 2027, offsetting loss of exclusivity and driving revenue growth.

• AI integration, external innovation, and partnerships—including the Longboard Pharmaceuticals acquisition—are central to scaling R&D and commercial capabilities and expanding the neuro-rare pipeline.

• Capital allocation is optimized, reallocating DKK 1-1.3 billion from mature brands and non-core markets to fund innovation, improve margins, and support strategic launches.

• Operating model optimization aims to reduce sales & distribution cost ratio to 30%-35% of revenue by 2027 and maximize brand potential in key and specialty markets.

Commercial performance and market expansion

• U.S. growth is driven by patient-centric models, advanced analytics, and ambition to build multiple $1bn+ franchises, with Rexulti targeting $1.3bn annual sales and Vyepti leading migraine growth.

• Europe and international operations contribute about half of revenue, with Brintellix/Trintellix and Abilify LAI franchises showing strong growth and extended exclusivity in Japan.

• Commercial models are evolving to optimize capital spending, leverage partnerships, and adapt to market needs, especially in smaller and emerging markets.

• Neurospecialty and neuro rare franchises are being established, with Vyepti as a foundation and new assets like amlenetug and bexicaserin anchoring future growth.

• Global peak sales potential is projected at DKK 9 billion for Vyepti and over $1 billion for Rexulti (core indications).

R&D pipeline and clinical milestones

• Up to four new molecular entities (NMEs) are expected to enter phase III by 2026, including amlenetug, anti-PACAP, anti-ACTH, and bexicaserin.

• Vyepti is achieving blockbuster growth, with sales expected to triple by 2027 and expansion into Asia pending SUNRISE trial results.

• Bexicaserin is in phase III for developmental and epileptic encephalopathies, with breakthrough designation and strong efficacy and safety data.

• Amlenetug is progressing toward phase III for multiple system atrophy, showing 27% slowing of disease progression in phase II.

• Anti-PACAP and anti-ACTH programs are advancing, targeting high unmet needs in migraine and neurohormonal disorders, with significant market potential and late-decade launches.